Abrdn PLC Seagen Inc. Transaction History

Abrdn PLC

  • $50 Billion
  • Q1 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 06, 2023
SELL
$191.51 - $216.16 $68,177 - $76,952
-356 Reduced 1.45%
24,118 $5.12 Million
Q2 2023

Jun 20, 2024
SELL
$187.64 - $206.25 $33,399 - $36,712
-178 Reduced 0.72%
24,474 $4.71 Million
Q2 2023

Aug 04, 2023
SELL
$187.64 - $206.25 $33,399 - $36,712
-178 Reduced 0.72%
24,474 $4.71 Million
Q1 2023

Jun 20, 2024
BUY
$127.59 - $203.08 $1.49 Million - $2.36 Million
11,644 Added 89.51%
24,652 $4.99 Million
Q1 2023

Apr 28, 2023
BUY
$127.59 - $203.08 $1.49 Million - $2.36 Million
11,644 Added 89.51%
24,652 $4.99 Million
Q4 2022

Jun 20, 2024
BUY
$117.37 - $139.17 $1.53 Million - $1.81 Million
13,008 New
13,008 $1.67 Million
Q4 2022

Feb 09, 2023
BUY
$117.37 - $139.17 $96,830 - $114,815
825 Added 6.77%
13,008 $1.67 Million
Q3 2022

Nov 10, 2022
BUY
$135.27 - $180.11 $200,334 - $266,742
1,481 Added 13.84%
12,183 $1.67 Million
Q2 2022

Aug 05, 2022
SELL
$108.81 - $179.33 $45,809 - $75,497
-421 Reduced 3.78%
10,702 $1.89 Million
Q1 2022

May 04, 2022
SELL
$119.61 - $157.85 $27,390 - $36,147
-229 Reduced 2.02%
11,123 $1.6 Million
Q4 2021

Feb 08, 2022
BUY
$142.57 - $190.86 $76,132 - $101,919
534 Added 4.94%
11,352 $1.76 Million
Q3 2021

Nov 15, 2021
SELL
$142.45 - $169.82 $23,361 - $27,850
-164 Reduced 1.49%
10,818 $1.84 Million
Q2 2021

Aug 10, 2021
SELL
$135.08 - $161.1 $305,145 - $363,924
-2,259 Reduced 17.06%
10,982 $1.73 Million
Q1 2021

May 06, 2021
BUY
$137.51 - $190.8 $56,104 - $77,846
408 Added 3.18%
13,241 $1.84 Million
Q4 2020

Feb 10, 2021
BUY
$164.63 - $211.93 $2.11 Million - $2.72 Million
12,833 New
12,833 $2.25 Million

Others Institutions Holding SGEN

# of Institutions
40
Shares Held
1.26M
Call Options Held
23K
Put Options Held
55.2K
View Full List

About Seagen Inc.

SGEN Quotes by TradingView
  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Abrdn PLC Portfolio

Follow Abrdn PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email